D. E. Shaw & Co., Inc. Immunic, Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $100 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMUX
# of Institutions
75Shares Held
40.2MCall Options Held
1.14MPut Options Held
130K-
Bvf Inc San Francisco, CA8.9MShares$7.92 Million0.43% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT7.29MShares$6.49 Million0.66% of portfolio
-
Avidity Partners Management LP Dallas, TX4.45MShares$3.96 Million1.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.93MShares$3.5 Million0.0% of portfolio
-
Gratus Capital LLC2.11MShares$1.88 Million0.1% of portfolio
About IMMUNIC, INC.
- Ticker IMUX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 30,565,000
- Market Cap $27.2M
- Description
- Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...